No Data
No Data
No Data
No Data
No Data
Promising Preclinical Data and Positive Phase 2 Results Bolster Buy Rating for Elevation Oncology
TipRanksApr 9 06:17 ET
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
PR NewswireApr 8 16:30 ET
Express News | Watching Elevation Oncology; Traders Circulate M&A Blog Comments Saying 'The Intensity Of M&A Interest Among ADC Developers As Well As A Transactional ELEV Management Team Have Made This Company Hard To Ignore'
Moomoo 24/7Apr 3 10:10 ET
Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan
Merrimack Pharmaceuticals (MACK) said late Wednesday it has received a $225 million milestone payment from Ipsen and called for a special stockholder meeting on May 10 to approve a plan of dissolution
MT NewswiresMar 27 17:30 ET
HHS Says In 2025, All People With Medicare Part D Will Benefit From A $2,000 Cap On Annual Out-Of-Pocket Prescription Drug Costs
HHS Says In 2025, All People With Medicare Part D Will Benefit From A $2,000 Cap On Annual Out-Of-Pocket Prescription Drug Costs
BenzingaMar 26 08:54 ET
SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation of Elevation Oncology (ELEV) and Encourages Investors to Contact the Firm
Philadelphia, Pennsylvania--(Newsfile Corp. - March 14, 2024) - Kaskela Law LLC announces that it is investigating Elevation Oncology, Inc. (NYSE: ELEV) on behalf of the company's shareholders. The in
newsfileMar 14 08:15 ET
No Data
No Data